Parnax Lab

Parnax Lab Debt/Market Cap

The Debt to Market Capitalization Ratio of Parnax Lab (506128.BO) as of Nov 14, 2026 is 48.70 %. In the previous year, Debt to Market Capitalization Ratio was 56.49 % — a change of -13.78% (lower).

Debt/Market Cap

48.70 %

YoY

-13.78%

Last updated:

Debt to Market Capitalization Ratio of Parnax Lab is 2025 48.70 % . Debt to Market Capitalization Ratio of Parnax Lab was 2024 56.49 % . It decreases by -13.78% lower compared to the previous year.

The Parnax Lab Debt/Market Cap history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/Market Cap
Date
Debt/Market Cap
Jan 1, 2018
25.66 INR
Jan 1, 2019
29.38 INR
Jan 1, 2020
35.88 INR
Jan 1, 2021
41.26 INR
Jan 1, 2022
48.39 INR
Jan 1, 2023
38.33 INR
Jan 1, 2024
56.49 INR
Jan 1, 2025
48.70 INR
The Parnax Lab Debt/Market Cap history
YEARDebt/Market CapYoY
48.70 %-13.78%
56.49 %+47.37%
38.33 %-20.78%
48.39 %+17.27%
41.26 %+14.98%
35.88 %+22.15%
29.38 %+14.49%
25.66 %-40.81%
43.35 %-3.45%
44.90 %-3.89%
46.72 %+24.43%
37.54 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Parnax Lab Stock analysis

What does Parnax Lab do? Parnax Lab Ltd. generates revenue through manufacturing and exporting pharmaceutical formulations, including cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, geriatric special formulations, highly viscous products, and suspensions. The company trades pharmaceuticals and medicinal products, focusing on high-volume oral formulations for diverse consumer segments. Naxpar Pharma Private Limited serves as its subsidiary in these operations. The firm's primary customers are likely healthcare providers, pharmacies, and distributors within the pharmaceutical industry, though specific buyer details are not disclosed. Parnax Lab Ltd. operates through the pharmaceutical formulations segment, emphasizing export-driven manufacturing and trading activities. Its product portfolio targets various health needs, from pediatric to geriatric care, with a strong focus on oral delivery systems. Parnax Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Parnax Lab stock

Debt to Market Capitalization Ratio of Parnax Lab is 48.70 % in 2025.

Debt to Market Capitalization Ratio of Parnax Lab changed from 56.49 % to 48.70 %, representing a -13.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt to Market Capitalization Ratio Parnax Lab since 2006 – with annual values, charts, and detailed analysis.

Debt/Market Cap compares total debt to the market value of equity. It provides a market-based view of financial leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt to Market Capitalization Ratio's Parnax Lab with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Parnax Lab

All Key Metrics — Parnax Lab